During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
With integrated data for thousands of TCGA tumors, teams explored cancer subtypes, searched for prognostic insights, began mapping immune cell interactions, and more.
The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.
A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.
In Cell this week: variants linked to enhanced branching among tomatoes, innate and adaptive immune response to Zostavax vaccination, and more.
The researchers used mass cytometry to characterize dozens of markers in 3.5 million immune cells in samples from 73 clear cell renal cell carcinoma patients.
The companies will use Personalis' ACE ImmunoID next-generation sequencing platform to analyze tumor samples from clinical trials of Argos' drug.
In Genome Biology this week: variants linked to disorders of sex development, new candidate genes for ciliopathies, and more.
A renal cell carcinoma study revealed increased metabolic gene expression in PD-L1-positive tumors from individuals who did not respond to nivolumab.
In Genome Biology this week: methylation changes in aging, single-cell RNA sequencing of renal cell carcinoma tumor, and more.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.